Genfit - ADR

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné, and Bart Staels in September 1999 and is headquartered in Loos, France.

PARIS--(BUSINESS WIRE)--Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) have entered into a long-term strategic partnership for global collaboration between the two companies. The agreement gives Ipsen exclusive worldwide* license to develop, manufacture and commercialize GENFIT's investigational treatment elafibranor, for people living with Primary Biliary Cholangitis (PBC). The p

Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership

GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor , a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership

GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership

Lille, France; Cambridge, M A ; November 18 , 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, is proud to announce that NIS4® technology's utility has been recognized in a Stage 1 study1 undertaken by the Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE) initiative of the Foundation for the National Institutes of Health's Biomarkers Consortium as demonstrating a unique performance in identifying patients with “at-risk” Non-Alcoholic Steatohepatitis (NASH).

GENFIT: FNIH NIMBLE Study Demonstrates NIS4® Technology's Unique Performance in Identifying Patients with “at-risk” NASH

Lille, France; Cambridge, M A ; November 09 , 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced the first patient first visit for the evaluation of NTZ in subjects with hepatic impairment as part of its ACLF program.

GENFIT Announces First Patient First Visit for the Evaluation of NTZ in Subjects with Hepatic Impairment as part of its ACLF Program

Lille, France; Cambridge, M A ; November 8 , 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced its cash position as of September 30, 2021 and revenues for the first nine months of 20211.

GENFIT: Third Quarter 2021 Financial Information

Lille, France; Cambridge, MA; November 0 2 , 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced that it will be presenting new clinical data on its investigational compound elafibranor at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021 to be held from November 12 to November 15, 2021.

New Clinical Data on GENFIT's Investigational Compound Elafibranor to be Presented at AASLD The Liver Meeting®

GENFIT Reports First Half-Year 2021 Financial Results and Provides Corporate Update

L ille (France) ; C ambridge ( M assachusetts, United States) — June 30 , 202 1 — GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced the results of the voting by shareholders at the Combined Shareholders Meeting which took place on June 30, 2021 behind closed doors at the Company's headquarters.

GENFIT: June 30, 2021 Annual Shareholders Meeting results

Lille, France; Cambridge, M A ; June 24 , 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the securing of a €11 million non-dilutive loan guaranteed by the French government (known as a State-Guaranteed Loan or Prêt Garanti par l'Etat in French).

GENFIT obtains non-dilutive financing of €11 million in the form of a State Guaranteed Loan

Lille, France; Cambridge, M A ; June 2 3 , 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced it will be making two poster presentations at two internationally-renown scientific and medical events in June 2021, including a thought-leadership documentary featuring Key Opinion Leaders (KOLs).

GENFIT presents new NIS4® data in NASH at the International Liver Congress™ and the 81st Scientific Sessions of the American Diabetes Association

Lille, France; Cambridge , M A ; J une 15 , 202 1 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced that the June 15, 2021 Combined Shareholders Meeting obtained a wide support for the resolutions submitted to the shareholders vote, however, quorum was not met on first convening. A new Combined Shareholders Meeting to vote on the same agenda will be convened on June 30, 2021 at 2.30pm Paris time. The agenda and resolutions remain unchanged. The quorum on first convening amounted to 18.19%. As a reminder, on second convening the required quorum to validly deliberate at the Extraordinary General Meeting is 20%.

GENFIT: June 15, 2021 Combined Shareholders Meeting: Wide support for the resolutions submitted to the shareholders' vote but quorum not met on first convening

Lille, France; Cambridge, M A ; Ma y 27 , 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases (the “Company ”), today informs its shareholders of certain participation and organization procedures for the ordinary and extraordinary general meeting of June 15, 2021 (the “Combined General Meeting”) in accordance with decree n°2021-255 of March 9, 2021, extending the application of measures of ordinance n°2020-321 of March 25, 2020 and its application decree n°2020-418 of April 10, 2020 which was extended until July 31, 2021 by the decree n°2021-255 of March 9, 2021 (the “Decree”).

GENFIT Informs its Shareholders of Certain Procedures for the Combined General Meeting of June 15, 2021

(Unaudited financial information under IFRS)

GENFIT: Reports First Quarter 2021 Financial Information

Lille, France; Cambridge, M A ; May 11 , 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced a refocus of its R&D on acute on chronic liver failure (ACLF) and cholestatic diseases.

GENFIT Provides Pipeline Update and Launch of New Clinical Programs

Lille, France; Cambridge, M A ; May 10, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases (the “Company”), today announced that it published in the May 10, 2021 French legal announcements bulletin n°56 (Bulletin des Annonces Légales Obligatoires) its convening notice that the Combined Shareholders Meeting will be held on June 15, 2021, at 2:30pm, at the Company's headquarters, located at Parc Eurasanté, 885 avenue Eugène Avinée in Loos (59120), France.

GENFIT Annual Combined General Meeting of June 15, 2021 - Availability of Preparatory Documents

Lille, France; Cambridge, M A ; April 23 , 202 1 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the filing of its 2020 Universal Registration Document with the Autorité des marchés financiers (AMF) and its Annual Report on Form 20-F for the year ended December 31, 2020 with the U.S. Securities and Exchange Commission (SEC) and that its annual shareholders meeting will take place on Tuesday, June 15, 2021.

GENFIT: Publication of the 2020 Universal Registration Document and the 2020 Annual Report on Form 20-F; Annual Shareholders Meeting to take place on June 15, 2021

Lille, France; Cambridge , M A ; April 2 2 , 202 1 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced that Thomas Baetz has been appointed as Chief Financial Officer. Thomas Baetz joins the Executive Committee, along with Stefanie Magner, Chief Compliance Officer.

GENFIT hires Thomas Baetz as Chief Financial Officer and adds two new members to its Executive Committee

GENFIT Reports Full-Year 2020 Financial Results and Provides Corporate Update

Lille, France; Cambridge, MA; March 04, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the appointment of Jean-François Tiné as an independent board member.

GENFIT appoints Jean-François Tiné to the Board of Directors

Lille, France; Cambridge, MA; February 26, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced its cash position as of December 31, 2020 and revenues for 20202.

GENFIT: Revenues and Cash Position as of December 31, 2020

Lille, France; Cambridge, MA; February 22, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today discusses the highlights from its KOL Analyst Event on Primary Biliary Cholangitis (PBC), the therapeutic landscape and commercial opportunity. The event focused on GENFIT's new priority program. It provided KOL insights on PBC, details on GENFIT's Phase 2 data recently published in the Journal of Hepatology, highlights on the ongoing ELATIVE™ Phase 3 clinical trial, and projections on elafibranor's commercial opportunity. The PBC KOL analyst event replay can be accessed here .

GENFIT: new market research data highlight potential of elafibranor in PBC

Lille, France; Cambridge, MA; February 10, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced its provisional financial calendar for 2021.

GENFIT: 2021 Financial Calendar

Investors applauded the company's latest clinical results.

Why Genfit Stock Is Skyrocketing Today

The stock price of Genfit SA (NASDAQ: GNFT) is trading at over 30% pre-market as of 6:19 AM ET. This is why it happened.

GNFT Stock Price Increases Over 30% Pre-Market: Why It Happened

Genfit SA (NASDAQ: GNFT) shares shot up 150% in the after-hours trading today. What Happened: The France-based late-stage biopharmaceutical company said in the after-hours Tuesday that positive results from the Phase 2 trial evaluating elafibranor in patients with Primary Biliary Cholangitis have been published.

News for Genfit - ADR Stock (GNFT)